Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member...
-
Upload
junior-eary -
Category
Documents
-
view
226 -
download
0
Transcript of Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member...
![Page 1: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/1.jpg)
Slide No 1 • •
Corporate Social Responsibility
Lars Rebien Sørensen
CEO
Novo Nordisk A/S
Board Member
World Diabetes Foundation
![Page 2: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/2.jpg)
The number of people with diabetes in the world is expected to rise from 177 million today to 370 million in 2030
76% of the total number of people with diabetes worldwide will be living in the developing countries
![Page 3: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/3.jpg)
The developing countries carry 90% of this world’s total disease burden, yet they benefit from only 10% of global health resources
WHO estimates that 1/3 of the world population lacks regular access to essential drugs, and this figure is expected to rise to over 50% in the least developed parts of Africa and Asia
![Page 4: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/4.jpg)
WHO states that non-communicable diseases such as diabetes are the world’s main disablers and killers already now
![Page 5: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/5.jpg)
Slide No 5 • •
Epidemiology: Burden of diabetes is increasing
• Increased childhood and adult obesity• Decreasing levels of physical activity• Increasing urbanisation• Increased longevity• Earlier diagnosis
A new patient is diagnosed with type 2 diabetes every 5 minutes
Epidemic(WHO, 1997)
![Page 6: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/6.jpg)
Slide No 6 • •
The sufferings from diabetes
• Life expectancy is reduced by 5 to 10 years
• Premature death due to myocardial disease X 4
• Stroke is increased X 2
• Renal failure: 40% of all dialysed patients have diabetes
• New blindness: 30% of all cases are people with diabetes (>90% of these have type 2 diabetes)
• Two out of three amputees have diabetes
![Page 7: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/7.jpg)
Slide No 7 • •
The financial costs of diabetes
”With the present trend diabetes and its complications, will take more than one third of the health budgets in only 15 to 20 years – if vigorous steps to slow theprogress of this ’epidemic’ are not taken”
S. Orahilly, Science, medicine and the future. Non-insulin-dependent diabetes mellitus: the gathering storm. BMJ March 1997
![Page 8: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/8.jpg)
Slide No 8 • •
What can a diabetes company do?
![Page 9: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/9.jpg)
Slide No 9 • •
• Financial• Socio-& health economics
• Employees • Patients• Communities
•Environment• Animals• Bioethics
Economically viable
Environmentally soundSocially responsible
The Triple Bottom Line
![Page 10: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/10.jpg)
Slide No 10 • •
Access to health in developing countries
WHO recommendations:
• Development of national health strategies
• Building of national healthcare capacity
• Best possible pricing
• Additional funding
![Page 11: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/11.jpg)
Slide No 11 • •
Diabetes a national priority?
![Page 12: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/12.jpg)
Slide No 12 • •
Diabetes prevention programme
NCD Unit for prevention /control
National survey for hypertension
No surveillance system nationally
NCD policy
Budget line for NCD
Integrated primary care prevention
NCD info in annual report
Focus on chronic diseases? (167 countries)
Alwan 2001
![Page 13: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/13.jpg)
Slide No 13 • •
National Diabetes Strategies programme
• Novo Nordisk facilitates development and collaboration on the implementation of national strategies for diabetes prevention and treatment
• We aim at identifying best practices from around the world
• The programme is systematic and can be a template for the other chronic diseases (CVD, hypertension)
![Page 14: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/14.jpg)
Slide No 14 • •
Understanding patients needs
![Page 15: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/15.jpg)
Slide No 15 • •
DAWN- A study to understand…
• People with diabetes • Feelings, worries,
wishes and needs
• Perceptions of their diabetes
• Health care professional attitudes
• Role of psychosocial factors
![Page 16: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/16.jpg)
Slide No 16 • •
Best Pricing
![Page 17: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/17.jpg)
Slide No 17 • •
Pricing Policy in LDC Countries
• Novo Nordisk offers its insulin products to the public health systems in the poorest countries at prices not to exceed 20% of the average price in North America, Europe and Japan
LDC as defined by UN: 49 countries in Africa, Asia-Pacificand Central America
![Page 18: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/18.jpg)
Slide No 18 • •
Additional funding
![Page 19: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/19.jpg)
The World Diabetes Foundation founded in March2002
Initiated by a grant from Novo Nordisk of USD 80 million Majority of board members – non Novo NordiskChairman: Professor Pierre Lefèbvre26 projects funded to date
![Page 20: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/20.jpg)
WDF is dedicated to prevention and treatment of diabetes in the poorest countries with focus on:
Awareness about diabetesPrevention of diabetes and its complications Education and training for patients and professionalsAccess to essential diabetes medicationDetection, treatment and monitoring of diabetes
![Page 21: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/21.jpg)
The role of the World Diabetes Foundation
Creates partnerships and acts as a catalyst
Links people and resources to advocate globally and provide care locally
Aims at the poorest of the poor
Focuses on innovative strategies to prevent diabetes
Strives to achieve sustainable solutions
![Page 22: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/22.jpg)
![Page 23: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/23.jpg)
Regional projects in WDF portfolio
• Diabetes Education, Sub-Saharan Africa• Clinical Practice Guidelines, Sub-Saharan Africa• WDF/IDF Fellowships• Nutrition Protocol, the Caribbean• Postgraduate diabetes training, Africa
![Page 24: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/24.jpg)
Local projects in WDF portfolio
• Cameroon: National Diabetes Programme• China: National Diabetes Programme• India: Diabetes Eye Care• India: National Diabetes Programme• India/Tanzania: Diabetes Foot Care• India: Rural and semi-urban diabetes
prevention and control• Tanzania: 15 Diabetes Clinics• Mozambique: Insulin Availability • West Bank: Diabetes Prevention and Nutrition• Cuba: Regional Diabetes Centers • Congo / Kinshasa: Insulin Availability• Vietnam: National Diabetes Project • Bolivia: Diabetes Centre• Nepal: Diabetes Education and Prevention• Bhutan: Diabetes health care services• Pacific Islands: Reducing diabetes
complications
![Page 25: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/25.jpg)
Memorandum of Understanding with DANIDAMemorandum of Understanding with DANIDA- Danish International Development Agency- Danish International Development Agency
The objective of the partnership is to combat diabetes in the developing countries
Lead to the identification of two projects in India and Bhutan
![Page 26: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/26.jpg)
Application criteriaApplication criteria
SustainabilityLocal championPolitical willCo-fundingApplication form on www.worlddiabetesfoundation.org
![Page 27: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/27.jpg)
Multiplier effectMultiplier effect
Project portfolio:21 million USD of which 12 million USD were donated by the World Diabetes Foundation
![Page 28: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/28.jpg)
ImpactImpact
The projects funded by the World Diabetes Foundation will in the coming 3-4 years potentially influence the diabetes treatment of 18,000.000 people directly and indirectly 50,000,000 people in the developing countries
![Page 29: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/29.jpg)
Slide No 29 • •
“The hottest places in Hellare reserved for those who,in time of great moral crisis,maintain their neutrality” Dante
![Page 30: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/30.jpg)
Slide No 30 • •
“…Governments only find the courage and resources to do the right thing whenbusiness takes the lead.”
Kofi Annan
![Page 31: Slide No 1 Corporate Social Responsibility Lars Rebien Sørensen CEO Novo Nordisk A/S Board Member World Diabetes Foundation.](https://reader035.fdocuments.us/reader035/viewer/2022062217/56649c7c5503460f94930e3a/html5/thumbnails/31.jpg)
Slide No 31 • •
Need for a new and different understanding of the disease
Need for a new social equation in disease management
An urgent need that governments, scientists, corporations, patients join forces against the disease
Thank you!